IP Library Granted Patent US 8,703,438
Granted Patent B2
US 8,703,438 · App. 12/621,290 · Granted Apr 22, 2014

Ligand binding stabilization method for drug target identification

Inventors: Jing Huang (Los Angeles, CA); Brett Eugene Lomenick (Los Angeles, CA); Rui Hao (Los Angeles, CA); Nao Jonai (Yokohama, JP); Thomas M. Vondriska (Los Angeles, CA); Sarah Warburton (Los Angeles, CA); Gregory Joseph Baker (Los Angeles, CA); Mariam Aghajan (Los Angeles, CA)
Assignee: The Regents of the University of California
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,703,438
App. No.
12/621,290
Granted
Apr 22, 2014
Kind
B2
Abstract

Drug affinity responsive target stability (DARTS) is a method of drug target ID with several significant advantages over current techniques. In certain embodiments the method involves contacting a sample comprising one or more protein target(s) with a test agent to form a sample/test agent mixture; contacting the mixture with a protease; and identifying a protein or protein fragment that is protected from proteolysis, wherein the protection from proteolysis is an indicator that the protein or protein fragment binds to or interacts with the test agent.

Claims (44)

1. A method of identifying a protein target that interacts with or is bound by a test agent, said method comprising:

contacting a test sample comprising a plurality of proteins with said test agent to form a sample/test agent mixture;

contacting said mixture with a protease where said protease is not said test agent;

determining the abundance of a protein in said test sample/test agent mixture and in a negative control sample lacking said test agent; and

identifying and/or selecting a protein or protein fragment that is protected from proteolysis, wherein said identifying comprises comparing the abundance of a protein in said test sample/test agent mixture to the abundance of a protein in said negative control sample, and the presence and/or abundance of a protein or protein fragment protected from proteolysis in said test sample is an indicator that said protein or protein fragment binds to or interacts with said test agent and is a target for said test agent.

2. The method of claim 1 , wherein said test sample comprises recombinantly expressed proteins.

3. The method of claim 1 , wherein said test sample comprises a cell or tissue lysate.

4. The method of claim 3 , wherein said cell or tissue lysate is from a healthy cell or tissue.

5. The method of claim 3 , wherein said cell or tissue lysate is from a diseased cell or tissue.

6. The method of claim 3 , wherein said cell or tissue lysate is from a cell or tissue having a mutated genome.

7. The method of claim 1 , wherein said test sample comprises a plurality of proteins selected from the group consisting of a human protein, a non-human mammalian protein, an insect protein, a fungal protein, an algal protein, a plant protein, a bacterial protein, and a viral protein.

8. The method of claim 1 , wherein said test sample comprises in vitro translated protein(s).

9. The method of claim 8 , wherein said in vitro translated proteins are produced in a system selected from the group consisting of a reticulolycte cell-free system, a wheat germ cell free system, and an E. coli cell free system.

10. The method of claim 1 , wherein said protease comprises a protease selected from the group consisting of a serine protease, a threonine protease, a cysteine protease, an aspartate protease, a metalloprotease, and a glutamic acid protease.

11. The method of claim 1 , wherein said protease comprises a mixture of one or more endopeptidases and exopeptidases.

12. The method of claim 1 , wherein said protease comprises subtilisin or thermolysin.

13. The method of claim 1 , wherein said protease comprises pronase.

14. The method of claim 1 , wherein said identifying comprises a method selected from the group consisting of a 1D electrophoresis, a 2-D electrophoresis, a chromatography, a capillary electrophoresis, a Western blot, and a mass spectrograph.

15. The method of claim 1 , wherein said identifying comprises 1D or 2D SDS PAGE and staining.

16. The method of claim 15 , wherein said method further comprises removing a band of the SDS page gel that shows altered protein abundance and performing mass spectrograph on the protein from said band.

17. The method of claim 1 , wherein said test agent is a human or veterinary pharmaceutical.

18. The method of claim 1 , wherein said test agent is selected from the group consisting of a metabolite, a herbal or other plant extract, a food component, a food additive, an agricultural pesticide or herbicide, a preservative, a colorant, a fragrance, an environmental agent, and a nanoparticle.

19. A method of identifying a protein target that interacts with or is bound by a test agent, said method comprising:

contacting a test sample comprising a plurality of proteins with said test agent to form a sample/test agent mixture;

contacting said mixture with a protease where said protease is not said test agent;

determining the abundance of a protein in said test sample/test agent mixture and in a negative control sample lacking said test agent; and

identifying and/or selecting a protein or protein fragment whose proteolysis is increased, wherein said identifying comprises comparing the abundance of a protein in said test sample/test agent mixture to the abundance of a protein in said negative control sample where an increase in proteolysis of a protein or protein fragment in said test sample is an indicator that said protein or protein fragment binds to or interacts with said test agent and is a target for said test agent.

20. The method of claim 19 , wherein said test sample comprises recombinantly expressed proteins.

21. The method of claim 19 , wherein said test sample comprises a cell or tissue lysate.

22. The method of claim 21 , wherein said cell or tissue lysate is from a healthy cell or tissue.

23. The method of claim 21 , wherein said cell or tissue lysate is from a diseased cell or tissue.

24. The method of claim 21 , wherein said cell or tissue lysate is from a cell or tissue having a mutated genome.

25. The method of claim 19 , wherein said test sample comprises one or more proteins selected from the group consisting of a human protein, a non-human mammalian protein, an insect protein, a fungal protein, an algal protein, a plant protein, a bacterial protein, and a viral protein.

26. The method of claim 19 , wherein said test sample comprises in vitro translated protein(s).

27. The method of claim 26 , wherein said in vitro translated proteins are produced in a system selected from the group consisting of a reticulolycte cell-free system, a wheat germ cell free system, and an E. coli cell free system.

28. The method of claim 19 , wherein said protease comprises a protease selected from the group consisting of a serine protease, a threonine protease, a cysteine protease, an aspartate protease, a metalloprotease, and a glutamic acid protease.

29. The method of claim 19 , wherein said protease comprises a mixture of one or more endopeptidases and exopeptidases.

30. The method of claim 19 , wherein said protease comprises subtilisin or thermolysin.

31. The method of claim 19 , wherein said protease comprises pronase.

32. The method of claim 19 , wherein said identifying comprises a method selected from the group consisting of a 1D electrophoresis, a 2-D electrophoresis, a chromatography, a capillary electrophoresis, a Western blot, and a mass spectrograph.

33. The method of claim 19 , wherein said identifying comprises 1D or 2D SDS PAGE and staining.

34. The method of claim 33 , wherein said method further comprises removing a band of the SDS page gel that shows altered protein abundance and performing mass spectrograph on the protein from said band.

35. The method of claim 19 , wherein said test agent is a human or veterinary pharmaceutical.

36. The method of claim 19 , wherein said test agent is selected from the group consisting of a metabolite, a herbal or other plant extract, a food component, a food additive, an agricultural pesticide or herbicide, a preservative, a colorant, a fragrance, an environmental agent, and a nanoparticle.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 9, 2010
From: HUANG, JING; LOMENICK, BRETT E; VONDRISKA, THOMAS M.; JONAI, NAO; HAO, RUI; BAKER, GREGORY J; AGHAJAN, MARIAM; WARBURTON, SARAH
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 024214/0046 →
CONFIRMATORY LICENSE Recorded Nov 30, 2009
From: UNIVERSITY OF CALIFORNIA-LOS ANGELES
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 023579/0423 →
Continuity (2)
Provisional Application 61115890 · Nov 18, 2008
Related Publication 20100184112A1 · Jul 22, 2010